CONCERT PLUS

TerminatedPhase 3

An Extension of the CONCERT Protocol (DIM18)

An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease

Lead sponsor

Medivation, Inc.

Asset

Dimebon

Listed sites

Recruiting sites

Enrollment

672

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•MMSE 12-24

Primary endpoint

•Safety

Identifiers

Registered as

Org study IDDIM18EXT

NCT IDNCT01152216

Timeline

Milestones

Study start2010-04 (month precision)

Study first posted2010-06-29estimated

Primary completion2012-05actual (month precision)

Last update posted2016-09-27estimated

Assets

Drug assets

Dimebon

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Successful completion of the 12 month DIM18 CONCERT study

•Mild-to-moderate Alzheimer's disease

•Probable AD, Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revised (DSM-IV-TR)

•Mini-Mental State Exam (MMSE) score between 12 and 24, inclusive

•Stable on donepezil for at least 6 months

Exclusion criteria

•Other causes of dementia

•Major structural brain disease

•Unstable medical condition or significant hepatic or renal disease

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Safety

Time frame:Through study discontinuation

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.